[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Pfizer new antiviral", "description": "Protectors from hospitalisation, the story so far.\nOral meds than can be prescribed from home with onset of symptoms\n\nMolnupiravir, approved by MHRA\n\nhttps://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra\n\nThe antiviral was found to be safe and effective following a stringent review of the available evidence.\n\nhttps://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/\n\nPublic domain data, Merck press release\n\n$ 700 per 5-day course\n\nUnder 50% reduction in deuteriation\n\nEffect of early treatment with fluvoxamine\n\nTogether Trial group\n\nPublic domain data, Peer reviewed trial in the Lancet\n\nhttps://clinicaltrials.gov/ct2/show/NCT04727424\n\nhttps://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltext\n\nAdults with a risk factor\n\n$4 for a 10-day course\n\n32% protection against hospitalization\n\n32% protection against death\n\nFluvoxamine is approved by the Food and Drug Administration as an antidepressant\n\nDoctors already can prescribe it off-label \u2014 using their clinical judgment\n\nhttps://www.washingtonpost.com/science/2021/10/28/antidepressant-fluvoxamine-coronavirus-lancet/?\n\nhttps://bnf.nice.org.uk/drug/fluvoxamine-maleate.html\n\nhttps://www.togethertrial.com\n\nIvermectin, Together trial results not yet released\n\n\nPFIZER\u2019S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDY\n\nhttps://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate\n\nPublic domain data, Pfizer press release\n\nPAXLOVID\u2122 (PF-07321332; ritonavir)\n\nFound to reduce the risk of hospitalization or death by 89% \n\nCompared to placebo in non-hospitalized high-risk adults with COVID-19\n\nThrough Day 28\n\nPAXLOVID group\n\nNo deaths\n\nPlacebo group\n\n10 deaths\n\nPfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possible\n\nPhase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) \n\nRandomized, double-blind study of non-hospitalized adult patients with COVID-19, \n\nwho are at high risk of progressing to severe illness \n\nScheduled interim analysis\n\n89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo\n\nIn patients treated within 3 days of symptom onset\n\nPAXLOVID group\n\n0.8% of patients hospitalized\n\n3/389 hospitalized with no deaths\n\nPlacebo group\n\n7.0% of patients hospitalized or died\n\n27/385 hospitalized\n\nwith 7 subsequent deaths\n\n(p less than 0.0001) 1 in 10,000 chance\n\nIn patients treated within 5 days of symptom onset\n\nPAXLOVID group\n\n1.0% of patients hospitalized\n\n6/607 hospitalized with no deaths\n\nPlacebo group\n\n6. 7% of patients hospitalized or died\n\n41/612 hospitalized,\n\nwith 10 subsequent deaths\n\np less than 0.0001\n\nAt the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), Pfizer will cease further enrollment into the study\n\ndue to the overwhelming efficacy demonstrated in these results\n\nAbout the Phase 2/3 EPIC-HR Study Interim Analysis\n\n1,219 adults enrolled out of 3,000 planned\n\nNorth and South America, Europe, Africa, and Asia\n\nEnrolled individuals had a laboratory-confirmed diagnosis of SARS-CoV-2 infection\n\nMild to moderate symptoms\n\nAt least one characteristic or underlying medical condition\n\nRandomized (1:1) to receive PAXLOVID\u2122 or placebo orally every 12 hours for five days\n\nAbout the Phase 2/3 EPIC-HR Study Safety Data\n\nSafety data, n = 1881\n\nTreatment-emergent adverse events\n\nPAXLOVID\u2122group\n\n 19%\n\nPlacebo group\n\n21%\n\nMost of which were mild in intensity\n\nFewer serious adverse events\n\nPAXLOVID\u2122group\n\n 1.7%\n\nPlacebo group\n\n6.6%\n\nDiscontinuation of study drug due to adverse events\n\nPAXLOVID\u2122group\n\n2.1%\n\nPlacebo group\n\n4.1%\n\nPharmacology\n\nSpecifically designed SARS-CoV-2-3CL protease inhibitor,\n\nan enzyme that the coronavirus needs to replicate\n\nCo-administration with a low dose of ritonavir helps slow the metabolism of PF-07321332\n\nPF-07321332 inhibits viral replication at a stage known as proteolysis, \n\nwhich occurs before viral RNA replication\n\nIn preclinical studies, PF-07321332 did not demonstrate evidence of mutagenic DNA interactions.\n\nEPIC-SR includes a cohort of vaccinated patients who have an acute breakthrough symptomatic COVID-19 infection and who have risk factors for severe illness.", "link": "https://www.youtube.com/watch?v=EMfjtgli55Y", "date_published": "2021-11-07 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]